BridgeBio Oncology Therapeutics, Inc. (BBOT)

NASDAQ: BBOT · Real-Time Price · USD

4.770

-0.120 (-2.45%)

At close: Sep 18, 2026, 4:00 PM EDT

4.834

+0.064 (1.34%)

After-hours: Sep 18, 2026, 7:30 PM EDT

BBOT Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Selling, General & Admin	36.8	24.62	7.76	8.49
Research & Development	162.15	121.2	73.11	56.29
Operating Expenses	198.96	145.82	80.86	64.77
Operating Income	-198.96	-145.82	-80.86	-64.77
Interest & Investment Income	15.36	11.34	6.38	0.07
Other Non Operating Income (Expenses)	1.48	0.43	0.21	-
Pretax Income	-182.11	-134.04	-74.28	-64.7
Net Income	-182.11	-134.04	-74.28	-64.7
Net Income to Common	-182.11	-134.04	-74.28	-64.7
Net Income Growth	-	-	-	-
Shares Outstanding (Basic)	71	31	0	0
Shares Outstanding (Diluted)	71	31	0	0
Shares Change	12503.20%	241276.23%	-89.66%	-
EPS (Basic)	-2.56	-4.30	-5756.41	-518.73
EPS (Diluted)	-2.56	-4.30	-5756.41	-518.73
EPS Growth	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Free Cash Flow	-151.56	-114.5	-55.08	-52.49
Free Cash Flow Per Share	-2.13	-3.68	-4268.47	-420.87
EBITDA	-198.65	-145.54	-80.66	-64.68
D&A For EBITDA	0.31	0.28	0.21	0.09
EBIT	-198.96	-145.82	-80.86	-64.77